For adult patients with brainstem high-grade gliomas, surgically removing the entire tumor may add many months or potentially years of survival beyond that offered by radiation and chemotherapy, according to results of a medical records study led by researchers at the Johns Hopkins Kimmel Cancer Center.
The National Comprehensive Cancer Network published new guidelines for treating children, adolescents and young adults with pediatric aggressive mature B-cell lymphomas, including Burkitt lymphoma and diffuse large B-cell lymphoma.
In a study of more than 1,600 patients with breast cancer undergoing chemotherapy, researchers found several associations between supplement use.
Treatment with the investigational single-agent belantamab mafodotin resulted in a 31% overall response rate with the 2.5 mg/kg regimen in patients with heavily pre-treated multiple myeloma.
A new analysis shows that a donor stem cell transplant following treatment with an immune checkpoint inhibitor is generally safe and produces good outcomes for patients with Hodgkin lymphoma, easing concerns that these patients are at heightened risk for severe immune-related complications.
Bristol-Myers Squibb Co. said the pivotal study of lisocabtagene maraleucel (liso-cel) an investigational CD19-directed CAR T-cell therapy with a defined composition of purified CD8+ and CD4+ CAR T cells in relapsed/refractory large B-cell lymphomas (TRANSCEND NHL 001) met its primary and secondary endpoints while demonstrating durable responses.
Phase II KarMMa study of ide-cel in relapsed, refractory multiple myeloma meets ORR primary endpoint
Results from the KarMMa study, a pivotal, open-label, single arm, multicenter, phase II study of idecabtagene vicleucel met its primary endpoint of overall response rate in the treatment of relapsed and refractory multiple myeloma.
Seattle Genetics Inc. announced positive pivotal data from the HER2CLIMB trial evaluating tucatinib in patients with HER2-positive metastatic breast cancer.
The presence of circulating tumor DNA in early-stage triple-negative breast cancer helped predict the risk of recurrence in women who had undergone surgery after neoadjuvant chemotherapy, a study found.
The phase III E1912 clinical study showed superior progression-free survival and overall survival in patients with chronic lymphocytic leukemia new to treatment.
